A RANDOMISED TRIAL OF DENTRIC CELL VACCINATION WITH NY-ESO-1 AND ALPHA- GALACTOSYLCERAMIDE IN PATIENTS WITH METASTATIC MELANOMA (ACTRN12612001101875)

被引：0
|
作者：
Dasyam, N. [1 ]
Sharples, K. [2 ]
Barrow, C. [3 ]
Bauer, E. [1 ]
Mester, B. [1 ]
McCusker, M. [4 ]
Painter, G. [5 ]
Weinkove, R. [3 ]
Brimble, M. [6 ]
Dunbar, R. [6 ]
Gasser, O. [1 ]
Hermans, I. [1 ]
机构：
[1] Malaghan Inst Med Res, Wellington, New Zealand
[2] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
[3] Wellington Reg Hosp, Capital Coast Dist Hlth Board, Wellington, New Zealand
[4] Univ Auckland, Canc Trials New Zealand, Auckland, New Zealand
[5] Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand
[6] Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
来源：
CYTOTHERAPY | 2021年 / 23卷 / 05期
关键词：
Vaccine;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
427
引用
收藏
页码：S98 / S98
页数：1
相关论文
共 44 条
  • [31] Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Yuan, Jianda
    Adamow, Matthew
    Ginsberg, Brian A.
    Rasalan, Teresa S.
    Ritter, Erika
    Gallardo, Humilidad F.
    Xu, Yinyan
    Pogoriler, Evelina
    Terzulli, Stephanie L.
    Kuk, Deborah
    Panageas, Katherine S.
    Ritter, Gerd
    Sznol, Mario
    Halaban, Ruth
    Jungbluth, Achim A.
    Allison, James P.
    Old, Lloyd J.
    Wolchok, Jedd D.
    Gnjatic, Sacha
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (40) : 16723 - 16728
  • [32] A dendritic cell targeting NY-ESO-1 vaccine significantly augments early and durable immune responses in melanoma patients pretreated with human Flt-3 Ligand
    Bhardwaj, Nina
    Friedlander, Philip
    Pavlick, Anna
    Ernstoff, Marc
    Gastman, Brian
    Hanks, Brent
    Albertini, Mark
    Luke, Jason
    Yellin, Michael
    Keler, Tibor
    Davis, Thomas
    Vitale, Laura
    Blazquez, Ana
    Morishima, Chihiro
    Danaher, Patrick
    Warren, Sarah
    Salim, Bob
    Hess, Bruce
    D'Amico, Leonard
    Lundgren, Lisa
    Disis, Nora
    Cheever, Martin
    Fling, Steven
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [33] Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
    Klein, Oliver
    Davis, Ian D.
    McArthur, Grant A.
    Chen, Li
    Haydon, Andrew
    Parente, Phillip
    Dimopoulos, Nektaria
    Jackson, Heather
    Xiao, Kun
    Maraskovsky, Eugene
    Hopkins, Wendie
    Stan, Rodica
    Chen, Weisan
    Cebon, Jonathan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 507 - 518
  • [34] Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
    Oliver Klein
    Ian D. Davis
    Grant A. McArthur
    Li Chen
    Andrew Haydon
    Phillip Parente
    Nektaria Dimopoulos
    Heather Jackson
    Kun Xiao
    Eugene Maraskovsky
    Wendie Hopkins
    Rodica Stan
    Weisan Chen
    Jonathan Cebon
    Cancer Immunology, Immunotherapy, 2015, 64 : 507 - 518
  • [35] Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
    Valmori, D
    Dutoit, V
    Liénard, D
    Rimoldi, D
    Pittet, MJ
    Champagne, P
    Ellefsen, K
    Sahin, U
    Speiser, D
    Lejeune, F
    Cerottini, JC
    Romero, P
    CANCER RESEARCH, 2000, 60 (16) : 4499 - 4506
  • [36] Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report
    Xia, Yan
    Tian, Xiaopeng
    Wang, Juntao
    Qiao, Dongjuan
    Liu, Xianhao
    Xiao, Liang
    Liang, Wenli
    Ban, Dongcheng
    Chu, Junjun
    Yu, Jiaming
    Wang, Rongfu
    Tian, Geng
    Wang, Mingjun
    ONCOLOGY LETTERS, 2018, 16 (06) : 6998 - 7007
  • [37] Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma
    Sabado, Rachel Lubong
    Pavlick, Anna C.
    Gnjatic, Sacha
    Ott, Patrick Alexander
    Hasan, Farah
    Spadaccla, Meredith
    Vengco, Isabelita
    Holman, Rose Marle
    Muren, Caroline
    Escano, Crystal
    Yepes, Ethel
    Stein, Claire
    Jungbluth, Achim A.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Bhardwaj, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.
    Cebon, Jonathan S.
    McArthur, Grant A.
    Chen, Weisan
    Davis, Ian D.
    Gore, Martin Eric
    Thompson, John F.
    Millward, Michael
    Findlay, Michael P. N.
    Dunbar, Rod
    Ottensmeier, Christian H. H.
    Venhaus, Ralph Rudolph
    Nathan, Paul D.
    Dalgleish, Angus George
    Cerundolo, Vincenzo
    Maraskovsky, Eugene
    Hopkins, Wendie
    Marsden, Jeremy
    Smithers, B. Mark
    Hersey, Peter
    Evans, T. R. Jeffry
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
    Pavlick, Anna C.
    Blazquez, Ana
    Meseck, Marcia
    Donovan, Michael J.
    Castillo-Martin, Mireia
    Thin, Tin Htwe
    Sabado, Rachel
    Mandeli, John P.
    Gnjatic, Sacha
    Friedlander, Philip Adam
    Bhardwaj, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
    Kawai, Akira
    Ishihara, Mikiya
    Nakamura, Tomoki
    Kitano, Shigehisa
    Iwata, Shintaro
    Takada, Kohichi
    Emori, Makoto
    Kato, Koji
    Endo, Makoto
    Matsumoto, Yoshihiro
    Kakunaga, Shigeki
    Sato, Eiichi
    Miyahara, Yoshihiro
    Morino, Kunihiko
    Tanaka, Shinya
    Takahashi, Shuichi
    Matsuo, Fujio
    Matsumine, Akihiko
    Kageyama, Shinichi
    Ueda, Takafumi
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5069 - 5078
12345